Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 23, 2026

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

View original at finance.yahoo.com

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Novo Nordisk has achieved tremendous success in the cardiometabolic treatment space, driven primarily by its semaglutide medicines
60% confidence
Novo Nordisk remained the market leader with a total GLP-1 volume market share of 54.6% globally across diabetes and obesity care as of December 2025-end
60% confidence
Structure Therapeutics represents a potential disruptor aiming to capture future share with innovative treatments
60% confidence

Data points we hold from this source

Novo Nordisk · market share

54.6 percent